177Lu-DOTATATE peptide receptor radionuclide therapy in metastatic or advanced and inoperable primary neuroendocrine tumors of rare sites

The present study aimed at exploring the patient and imaging characteristics of primary neuroendocrine tumors (NETs) of rare sites who presented with metastatic and/or advanced inoperable stages and therefore was considered for peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE. A retr...

Full description

Saved in:
Bibliographic Details
Main Authors: Pradeep Thapa, Rahul Parghane, Sandip Basu
Format: Artigo
Language:Inglês
Published: Wolters Kluwer Medknow Publications 2017-07-01
Series:World Journal of Nuclear Medicine
Subjects:
177lu-dotatate
neuroendocrine tumor
peptide receptor radionuclide therapy
Online Access:http://www.thieme-connect.de/DOI/DOI?10.4103/1450-1147.207283
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items